title: Novel Molecular Targets for the Therapy of Urothelial Cancer.
abstract: First-line platinum-based chemotherapy combinations are considered standard-of-care in locally advanced and metastatic urothelial cancer. However, long-term outcomes, including disease-specific and overall survival, remain poor. In addition, a number of patients with advanced urothelial carcinoma have co-existing medical issues that preclude the use of conventional chemotherapy. Improvements in our understanding over the molecular mechanisms of urothelial cancer have led to first-generation clinical trials evaluating novel agents targeting molecular pathways that may be relevant, at least in sub-populations. Emerging information regarding outcome with agents targeting novel molecular targets in advanced urothelial cancer is discussed in this review.
authors.affiliation: University of Texas Medical Branch, Galveston, TX, U.S.A. Brjana@utmb.edu.
authors.forename: Bagi R P
authors.initials: BR
authors.lastname: Jana
authors.affiliation: University of Texas Medical Branch, Galveston, TX, U.S.A.
authors.forename: Yan
authors.initials: Y
authors.lastname: Zhou
mesh_terms: D002295:Carcinoma, Transitional Cell / Q000098:blood supply / Q000188:drug therapy*; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology; D058990:Molecular Targeted Therapy; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D015398:Signal Transduction / Q000187:drug effects; D019459:Urothelium / Q000473:pathology*
chemical_list: D007155:Immunologic Factors
keywords: Urothelial cancer; novel molecular targets; review; targeted therapy; transitional cell carcinoma